Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning StreakInvestors Business Daily • 12/12/25
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology PortfolioBusiness Wire • 12/12/25
Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 10/28/25
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire • 10/28/25
Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains?Zacks Investment Research • 10/28/25
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in AsiaBusiness Wire • 10/19/25
Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge MarketsSeeking Alpha • 10/16/25
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric StudyBusiness Wire • 10/12/25
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/07/25
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor EventBusiness Wire • 10/06/25
Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on InflammationBusiness Wire • 09/02/25
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2Zacks Investment Research • 08/06/25
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire • 08/06/25